Candidiasis Clinical Trial
Official title:
Clinical and Laboratorial Evaluation of the Effect of Sodium Hypochlorite, Chloramine T and Ricinus Communis Solutions in Candida Species Identified in the Biofilm of Total Prostheses and Palate of Total Edentulous Individuals.
Verified date | June 2017 |
Source | University of Sao Paulo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical study identified the Candida species from the palate and complete dentures of edentulous individuals with prostheses-related stomatitis (PRS) and evaluated the effect of disinfectant solutions for denture hygiene on Candida spp. Sixty participants were randomly assigned in 04 parallel groups (n = 15); They were oriented to brush their prostheses and the palate 3 times a day and immerse them in saline solution (C-control), 0.25% Sodium hypochlorite (HS0.25%), 10% Ricinus communis (RC10%) or 0.5% Chloramine T (CT 0.5%) for 20 minutes. Biofilm samples were collected from the prostheses and palate in the baseline, after 7 and 37 days of use of the solutions and seeded in CHROMagar Candida medium. After incubation period, the presumptive identification, incidence verification and quantification of Candida species growth (CFU count) were performed. To quantify biofilm with software ImageTool 3.0, the inner surface was disclosed (1% neutral red) and photographed at the end of each period. The Candidiasis remission was assessed by scores before and after the use of solutions by palate's phographs. Descriptive analyzes were used for the identification and incidence of Candida spp. Kruskal-Wallis and Friedman tests, with stepwise step-down post-test for cell growth; ANOVA and Tukey for biofilm removal; Frequency of scores for evolution of inflammation. Level of significance was 95%. The most incident species were C. albicans, followed by C. tropicalis, C. glabrata and C. krusei. HS 0.25% reduced the incidence of the three species on the prostheses and palate in the periods of 7 and 37 days; CT 0.5% promoted reduction of Candida spp. only in dentures. R. communis decreased the incidence of C. tropicalis in both collection sites. For CFU counts, HS 0.25% and CT 0.5% caused significant reduction. For biofilm removal, HS0.25% was the most effective (9.75 ± 12.6) and RC10% (15.92 ± 14.8) intermediate. All groups decreased protheses-related stomatitis. HS0.25% has potential for clinical use as total denture disinfectants. RC10% and CT0.5% require further studies to be indicated as alternative solutions.
Status | Completed |
Enrollment | 108 |
Est. completion date | July 1, 2016 |
Est. primary completion date | January 1, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: - providing consent prior to participation in the study; - being at least 18 years of age; - maxillary complete conventional denture in good state and 1 year of use; - dentures with biofilm in a internal surface; - moderate to severe signs of Candidiasis. Exclusion criteria: - presence oral mucosal lesions apart from Candidiasis; - systemic or local conditions which predispose to Candida spp. infection; - history of chemotherapy/ radiotherapy; - having taken or used antibiotics, steroidal agents, or antifungal agents in the three months prior to the study; - being scheduled to replace existing dentures with new ones during the period of the trial; - dentures with adaptation or retention problems; - already using palatal brushing or disinfectant solutions as a routine oral hygiene. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Sao Paulo |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical evaluation of the Candida species identified in the biofilm of total prostheses and palate of total edentulous individuals. | Biofilm samples were collected from the prosthesis and palate in the baseline and seeded in CHROMagar Candida medium. After incubation period, the presumptive identification, incidence verification and quantification of Candida species growth (CFU count) were performed. The inner surface of the denture was disclosed (1% neutral red) and photographed at the end to quantify the biofilm with the software ImageTool 3.0. The palate with Candidiasis was photographed and assessed by scores. | Baseline (without disinfection procedures) | |
Secondary | Clinical evaluation of the effect of Sodium hypochlorite, Chloramine T and Ricinus communis solutions after 7 days of use in Candida species identified in the biofilm of total prostheses and palate of total edentulous individuals. | Biofilm samples were collected from the prostheses and palate after 7 days of use of the solutions and seeded in CHROMagar Candida medium. After incubation period, the presumptive identification, incidence verification and quantification of Candida species growth (CFU count) were performed. To quantify the denture biofilm with software ImageTool 3.0, the inner surface of the denture was disclosed (1% neutral red) and photographed at the end of 7 days. The Candidiasis remission was photographed and assessed by scores after 7 days of use solutions. | 7 days of disinfection | |
Secondary | Clinical evaluation of the effect of Sodium hypochlorite, Chloramine T and Ricinus communis solutions after 37 days of use in Candida species identified in the biofilm of total prostheses and palate of total edentulous individuals. | Biofilm samples were collected from the prostheses and palate after 37 days of use of the solutions and seeded in CHROMagar Candida medium. After incubation period, the presumptive identification, incidence verification and quantification of Candida species growth (CFU count) were performed. To quantify the denture biofilm with software ImageTool 3.0, the inner surface of the denture was disclosed (1% neutral red) and photographed at the end of 37 days. The Candidiasis remission was photographed and assessed by scores after 37 days of use solutions. | 37 days of disinfection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01982071 -
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
|
Phase 4 | |
Completed |
NCT02391532 -
Effect of Probiotic Bacteria on Oral Candida in Frail Elderly
|
N/A | |
Completed |
NCT01447407 -
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
|
Phase 1 | |
Not yet recruiting |
NCT00889356 -
Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis
|
Phase 3 | |
Completed |
NCT00105144 -
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
|
Phase 3 | |
Completed |
NCT00163111 -
A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.
|
Phase 3 | |
Completed |
NCT00138502 -
Funguria in Hospitalized Patients
|
||
Not yet recruiting |
NCT04502277 -
Bioavailability of Flucanazole
|
Early Phase 1 | |
Completed |
NCT05044156 -
Investigation of the Relationship Between Salivary Histatine-5 Level and Vaginal Candidiasis in Women
|
||
Completed |
NCT01322698 -
Staging Candidiasis in ICU Patients
|
N/A | |
Terminated |
NCT01092832 -
A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients
|
Phase 3 | |
Terminated |
NCT00095316 -
Caspofungin Study for Fungal Infections in Adults in Critical Care Settings
|
Phase 3 | |
Completed |
NCT04122560 -
Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration
|
Phase 4 | |
Completed |
NCT02641717 -
Validity of Patient-Collected Wet Mounts
|
N/A | |
Recruiting |
NCT01253954 -
A Multicenter Observational Study of Invasive Candida Infections Among ICU Patients in China
|
N/A | |
Completed |
NCT00797420 -
Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers
|
Phase 1 | |
Completed |
NCT00734539 -
Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight
|
Phase 3 | |
Completed |
NCT00001937 -
Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients
|
Phase 3 | |
Completed |
NCT02666716 -
Pharmacokinetics of Fluconazole IV as Prophylaxis or Therapy to ICU Patients
|
||
Terminated |
NCT00692783 -
Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility
|
N/A |